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5 Regular genetic kit for CF mutations detection
L. Pop1, I. Ciuca1, L. Tamas2, Z. Popa3, I. Popa1, A. Anghel2. 1University
of Medicine and Pharmacy Victor Babes, Pediatric II Department, Timisoara,
Romania; 2University of Medicine and Pharmacy Victor Babes, Biochemistry,
Timisoara, Romania; 3Cystic Fibrosis Centre, Timisoara, Romania
Background: A characteristic aspect for Romania is the CF mutations heterogeneity
which leads to a reduced percentage of genotype identiﬁcation.
Objectives: Assessment of the efﬁcacy of a mixed panel for CF mutation detection
in Romanian patients.
Methods: We evaluated retrospectively 40 patients(pts) with typical CF, registered
in the National CF Center Timisoara. The genetic tests were performed using a
mixed panel − (29 mutations − panel 1) − ARM and another kit for 38 mutations
(panel 2) − PCR. 18 mutations were common to the two kits; the total number of
identiﬁable alleles was 49.
Results: The ﬁrst panel identiﬁed the following mutation, in order of frequency:
DF508, G542X, N1303K, 621 + 1 G>T, I148T, representing 17.2% from panel 1
mutation. We found the following patients genotypes: 21 pts with F508del/F508del,
10 pts with F508del/ x, 5 pts F508del/G542X, 1 patient F508del/ N1303K. In 3
pts with compound genotype non-F508del (I148T, N1303K or G542X), the other
alella could not be identiﬁed, complementary genetic testing done in parents have
ruled out the possibility of homozygous genotype for non-F508del. In 13 patients
(32.5%) we could not fully identify the genotypet, thus they were further tested
with panel 2.
Conclusions: Correspondence of kits with identiﬁed mutations in CF Romanian
patients is low, although kits contain the most frequent mutations used in Europe.
Genetic heterogeneity in Romania limits signiﬁcantly the possibility of detection
of both alleles, the diagnosis rate of heterozygote being reduced. The question of
using additional kits or methods like CF gene sequencing raise the issue of a very
high cost.
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Cystic ﬁbrosis (CF) is among the most common life-threatening autosomal recessive
disorders, with an estimated incidence of approximately 1 in 3500–4000 live
births in Caucasians. The disease is caused by mutations in the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) gene. Worldwide, the most frequent
mutation F508del accounts for 18−87% of CF chromosomes depending upon
ethnicity. This mutation decreases along a northwest to southeast gradient, and
shows a frequency of only around 25% in the Turkish population. In general, a
very high heterogeneity in pathogenic CFTR mutations has been reported in Turkish
patients.
We have developed a reverse-hybridization assay for the rapid and simultaneous
analysis of 24 CFTR mutations, as well as the IVS8 polyT (5T/7T/9T) variants.
The CF StripAssay TUR shows a coverage of around 60% of mutations found in
the Turkish population, which is more than any other commercial CF test currently
available. The assay is based on multiplex DNA ampliﬁcation and hybridization
to teststrips presenting a parallel array of allele-speciﬁc oligonucleotide probes for
each mutant and wild-type allele. The procedure is rapid, simple and convenient,
accessible to automation and requires very small amounts of samples, which is of
particular importance for prenatal diagnosis and newborn screening.
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Background: Identiﬁcation of both mutated CFTR allele in patients is extremely
important for early CF diagnosis, genetic counseling and patient speciﬁc treatment.
Patients and Methods: We selected 62 Polish CF patient presenting clinical
features of cystic ﬁbrosis (elevated sweat chloride >60mmol/L, visibly bronchopul-
monary disease, peribronchial alterations, abnormal chest X-ray) in whom at least
one mutated CFTR allele was unknown, after initial screening using INNO-LiPA
CFTR19 and INNO-LiPA CFTR17+Tn kits. In the next step of our diagnostic
procedure we sequenced whole 27 CFTR exons together with exon/intron junctions
followed by Multiplex Ligation-dependent Probe Assay analysis.
Results: We identiﬁed 43 different mutations, representing 98% of CF chromo-
somes, including 7 novel CFTR mutations (3600+1G>T; 341_353del13bp;
13_15delCCT; 80G>T; 1853_1863del11bp; 1811+90C>A; 4035_4038dupCCTA).
A signiﬁcant proportion (31/43) of the different mutations identiﬁed would not have
been detected by the recommended kits. The 39% of the mutations (17/43) occurred
with a relative frequency >1%, which illustrates that the identiﬁed mutations are
not all rare.
Conclusion: Variety of existing changes in Polish CF patients population cause that
the large quantity of them are not included in routine diagnostic panel, thus some
changes may escape detection. This make diagnostic problem, especially during
newborn screening procedure when identiﬁcation of both mutated CFTR allele is
very important to conﬁrm CF before the ﬁrst symptoms appeared. Recognition of
the most frequent mutation in Polish population will help to design DNA testing
strategies.
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For the DNA analysis of CFTR gene we use since autumn 2009 (the beginning of
newborn screening of cystic ﬁbrosis (CF) in CR) the kit Elucigene, which allows
the detection of 32 or 50 mutations of CFTR gene including the mutation D1152H.
Newborns numbered 84 485 were born and looked through for CF in the Moravian
part of the Czech Republic in two years period (1.12.2009 to 31.12.2011).
The mutation D1152H in CFTR gene was the second most frequent CF mutation
we detected in newborns.
The DNA analysis of CFTR gene was performed in 953 newborns and we found
7 alelles with the mutation D1152H in CFTR gene − 6 healthy heterozygotes and
one compound heterozygote with CFTR genotype: [N1303k] + [D1152H] without
clinical manifestations of cystic ﬁbrosis and with the normal value of chloride in
sweat in newborn age.
The phenotype asociated with mutation D1152H with an other CFTR mutation in
the trans position, there are only a very limited knowledge (phenotypic charac-
teristics: chronic sinopulmonal disease, bronchiectasis − about 70%, Pseudomonas
colonisation − less than 30%, the majority are panreatic sufﬁcient, the disease is
diagnosed on average at the age of 30 years.
Our adult patients with CFTR genotype: [F508del] + [D1152H] corresponds to
these phenotype, the diagnosis of CF was establised in 2011.
In male carriers of the CFTR mutation D1152H we conﬁrmed an origin by
determining the Y-chromosome haplogroup, a group of Y-chromosomes related
by descent from a set of STR markers PowerPlex® Y.
We analysed 7 male individuals and identiﬁcated two Y-chromosome haplogroups
both descendent from West Europe in D1152H carriers and an individual with
Jewish descent.
